体外循环诱导炎症反应临床表型的推导与验证
单中心回顾性队列研究基于2010-2020年Cleveland Clinic注册数据,纳入25,613例体外循环心脏手术患者,用K-means共识聚类分析围术期临床变量推导出α、β、γ三种临床表型。α表型患者年龄更大、合并症更多,术后住院时间更长、肾衰竭更多、死亡率更高,炎症与肾损伤生物标志物水平也更高。该表型划分是与生物标志物及预后相关的均质亚组,为体外循环炎症反应的精准医学管理奠定基础。
要点
- 体外循环心脏手术可聚类为α、β、γ三种临床表型
- α表型占24%,年龄大、合并症多,预后最差
- α表型术后IL-6、IL-8及尿NGAL、IL-18更高
核心结论
- 体外循环诱导的炎症反应可推导出与生物标志物和术后结局相关的三种临床表型。
研究设计与样本
- 单中心回顾性队列研究,使用Cleveland Clinic注册数据,纳入2010年1月至2020年3月体外循环心脏手术患者25,613例。
- 排除急诊手术、非体外循环手术、移植、胸腹降主动脉手术及计划性心室辅助装置置入者。
- 采用基于K-means的共识聚类分析围术期临床变量推导表型,并汇总炎症与肾损伤生物标志物及临床结局。
主要发现
- 共推导出α、β、γ三种临床表型,α表型n=6157(24%),β表型n=10572(41%),γ表型n=8884(35%)。
- α表型患者年龄更大、合并症更多,包括心衰和肾衰;β表型更年轻且多为男性;γ表型58%为女性且BMI更低。
- α表型住院时间更长(均值9天 vs β和γ均为6天,ASD分别为1.15和1.08),肾衰竭更多,死亡率更高。
- 术后即刻α表型的炎症生物标志物(IL-6、IL-8)和肾损伤生物标志物(尿NGAL、IL-18)高于β和γ表型。
临床怎么用
- 可依据围术期临床变量将体外循环心脏手术患者分为三种表型,识别预后较差的α表型患者。
- α表型患者术后炎症与肾损伤生物标志物更高、结局更差,提示需加强围术期监测与管理。
- 该表型分类为未来评估治疗效应异质性及精准医学干预奠定基础。
局限性
- 单中心回顾性队列研究,结论外推需谨慎。
- 生物标志物数据仅来自临床试验入组的子组患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Precision medicine aims to change treatment from a "one-size-fits-all" approach to customized therapies based on the individual patient. Applying a precision medicine approach to a heterogeneous condition, such as the cardiopulmonary bypass (CPB)-induced inflammatory response, first requires identification of homogeneous subgroups that correlate with biological markers and postoperative outcomes. As a first step, we derived clinical phenotypes of the CPB-induced inflammatory response by identifying patterns in perioperative clinical variables using machine learning and simulation tools. We then evaluated whether these phenotypes were associated with biological response variables and clinical outcomes. METHODS: This single-center, retrospective cohort study used Cleveland Clinic registry data from patients undergoing cardiac surgery with CPB from January 2010 to March 2020. Biomarker data from a subgroup of patients enrolled in a clinical trial were also included. Patients undergoing emergent surgery, off-pump surgery, transplantation, descending thoracoabdominal aortic surgery, and planned ventricular assist device placement were excluded. Preoperative and intraoperative variables of patient baseline characteristics (demographics, comorbidities, and laboratory data) and perioperative data (procedural data, CPB duration, and hemodynamics) were analyzed to derive clinical phenotypes using K-means-based consensus clustering analysis. Proportion of ambiguously clustered was used to assess cluster size and optimal cluster numbers. After clusters were formed, we summarized perioperative profiles, inflammatory biomarkers (eg, interleukin [IL]-6 and IL-8), kidney biomarkers (eg, urine neutrophil gelatinase-associated lipocalin [NGAL] and IL-18), and clinical outcomes (eg, mortality and hospital length of stay). Pairwise standardized difference was reported for all summarized variables. RESULTS: Of 36,865 eligible cardiac surgery cases, 25,613 met inclusion criteria. Cluster analysis derived 3 clinical phenotypes: α, β, and γ. Phenotype α (n = 6157 [24%]) included older patients with more comorbidities, including heart and kidney failure. Phenotype β (n = 10,572 [41%]) patients were younger and mostly male. Phenotype γ (n = 8884 [35%]) patients were 58% female and had lower body mass index (BMI). Phenotype α patients had worse outcomes, including longer hospital length of stay (mean = 9 days for α versus 6 for both β [absolute standardized difference {ASD} = 1.15] and γ [ASD = 1.08]), more kidney failure, and higher mortality. Inflammatory biomarkers (IL-6 and IL-8) and kidney injury biomarkers (urine NGAL and IL-18) were higher with the α phenotype compared to β and γ immediately after surgery. CONCLUSIONS: Deriving clinical phenotypes that correlate with response biomarkers and outcomes represents an initial step toward a precision medicine approach for the management of CPB-induced inflammatory response and lays the groundwork for future investigation, including an evaluation of the heterogeneity of treatment effect.
引用
- Milam AJ, Liang C, Mi J, et al. Derivation and Validation of Clinical Phenotypes of the Cardiopulmonary Bypass-Induced Inflammatory Response. Anesth Analg. 2022. PMID: 36730794. doi:10.1213/ANE.0000000000006247
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。